Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The company operates a generic drug portfolio that includes 5 market approved anti cancer drugs authorized for sale in Germany. These drugs are part of the FOLFOX and FOLFIRI regimens used to treat metastatic colorectal, gastric and lung cancers. Greenland Mines Ltd also holds a biosimilar biologics platform focused on…
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The company operates a generic drug portfolio that includes 5 market approved anti cancer drugs authorized for sale in Germany. These drugs are part of the FOLFOX and FOLFIRI regimens used to treat metastatic colorectal, gastric and lung cancers. Greenland Mines Ltd also holds a biosimilar biologics platform focused on oncology, comprising 2 off patent antibodies obtained from Reliance Life Sciences that serve as alternatives to reference therapeutics such as rituximab, trastuzumab and bevacizumab. In addition, the company maintains a proprietary gene therapy platform that uses the Klotho protein to address neurodegenerative conditions like Alzheimer’s disease and amyotrophic lateral sclerosis. In March 2026, Greenland Mines Ltd completed the acquisition of Greenland Mines Corp., which adds the development and mining of critical and precious minerals to its business activities.
We generate revenue primarily from the sale of its 5 market approved anti cancer drugs in Germany, which are distributed to hospitals and pharmacies for use in chemotherapy regimens. Revenue also comes from the 2 off patent biosimilar antibodies, which are marketed to oncology providers as cost effective alternatives to branded biologics. The gene therapy platform, while still in pre clinical development, is expected to create future revenue through licensing agreements, partnership collaborations, or eventual product sales after regulatory approval. Additionally, the recently acquired mining subsidiary is positioned to generate income from the extraction and sale of critical and precious minerals to industrial customers. The company may also earn royalties from its licensed technologies, including a 3 percent net sales fee on certain gene therapy products under its agreements with the Autonomous University of Barcelona.
In the oncology biosimilars market, Greenland Mines Ltd competes with large generic drug manufacturers such as Pfizer, Mylan, Amgen, Teva Pharmaceutical Industries, Celltrion, Sandoz and other firms that produce biosimilar versions of rituximab, trastuzumab and bevacizumab. The company’s advantage lies in its exclusive licensing agreement with Reliance Life Sciences, which grants access to proprietary manufacturing know how and regulatory data for these biosimilar candidates. In the gene therapy field, the company faces competition from academic groups and biotech firms pursuing neurodegenerative treatments, including Unity Biotechnology, but it holds an exclusive worldwide license from the Autonomous University of Barcelona for the secreted Klotho s KL protein, providing a proprietary edge in Alzheimer’s and ALS therapy development. The mining division, although newly entered, operates in a sector dominated by major multinational miners, yet it seeks to differentiate itself by targeting critical minerals that are essential for high technology and green energy applications.
The company serves hospitals, outpatient oncology clinics, and patients receiving chemotherapy through its generic drug and biosimilar oncology products. Its gene therapy candidates are intended for neurology departments, memory disorder centers and specialized treatment facilities that focus on Alzheimer’s disease and amyotrophic lateral sclerosis. The mining division will supply critical and precious minerals to manufacturers of electronic components, producers of renewable energy equipment and industrial users requiring these materials for production processes.
Sectors:Healthcare · Basic MaterialsSector rationaleThe company's primary revenue is generated from the sale of market-approved anti-cancer drugs and biosimilar antibodies sold to hospitals and pharmacies, and it maintains a gene therapy platform. The acquisition of Greenland Mines Corp. introduces a substantial second business line focused on the extraction and sale of critical and precious minerals to industrial customers, which falls under Basic Materials.Industries:Generic DrugsHealthcarePrimaryThe company generates its primary current revenue from the sale of 5 market-approved generic anti-cancer drugs in Germany and 2 off-patent biosimilar antibodies marketed as cost-effective alternatives to branded biologics.Gene and Cell TherapyHealthcareSecondaryThe company maintains a proprietary gene therapy platform using the Klotho protein to treat neurodegenerative conditions like Alzheimer's and ALS, with expected revenue from licensing and future product sales.Industrial MineralsBasic MaterialsSecondaryThrough its acquired mining subsidiary, the company extracts and sells critical and precious minerals to manufacturers of electronic components and renewable energy equipment.Classified using BQ-MICSCIK: 0001907223
Investment Thesis
▲ Bull case
Greenland Mines (GRMLW) has established a strategic pathway to unlock multi-metal value at Skaergaard through its partnership with GTK Mintec, which provides an end-to-end platform for metallurgical testing, environmental assessment, and process optimization critical for unlocking the full economic potential of the deposit's complex, fine-grained multi-metal mineralization. This collaboration is not merely additive but transformative, as GTK Mintec's expertise in fine-grained, polymetallic ores—particularly layered mafic intrusions like Skaergaard—enables the Company to design flowsheets that recover not only precious metals (Pd, Pt, Au) but also bulk critical metals (Fe, Ti, V) and specialty elements (Ga, Ge) from both primary ores and tailings streams. The program integrates with ongoing work on ore sorting, pre-concentration, and tailings management, creating a closed-loop system that maximizes resource efficiency and minimizes waste, directly addressing a key unspoken risk in complex deposits: metallurgical recovery uncertainty. By advancing this work in parallel with field campaigns and positioning it as a prerequisite for future development decisions, Greenland Mines is systematically de-risking the project's technical viability far beyond what resource drilling alone can achieve, signaling to investors that the project is advancing toward a bankable feasibility study with credible metallurgical foundations.
The North Atlantic processing strategy—anchored by the non-binding Letter of Intent with an Icelandic industrial site owner—represents a structural, long-term catalyst that could reduce life-of-mine energy costs by over $1 billion while enabling green production of palladium, platinum, gold, and critical metals. This is not a speculative idea but a concrete, phased plan leveraging Iceland's abundant geothermal and hydropower resources to displace diesel-based generation (which currently costs ~$0.20/kWh in remote Arctic operations) with renewable power potentially below $0.03/kWh. The strategy includes pre-processing in Greenland (crushing, ore sorting) to reduce shipment volumes, followed by low-carbon refining in Iceland, creating an integrated value chain that aligns with Western policy goals for secure, transparent, and geopolitically resilient critical mineral supply chains. Management's emphasis on existing brownfield sites in Iceland—offering refurbishable infrastructure, deep-water access, and skilled labor—further reduces capital intensity and timelines, turning a conceptual advantage into an actionable, near-term de-risking lever that enhances both project economics and ESG profile simultaneously, a dual benefit rarely achieved in mining developments.
The concurrent advancement of the Sarfartoq Rare Earths Project—secured via acquisition from Neo Performance Materials—creates a powerful diversification and strategic synergy with Skaergaard, transforming Greenland Mines from a single-project precious metals play into a vertically integrated North Atlantic critical minerals corridor. Sarfartoq provides direct access to Nd-Pr, the two most valuable rare earth elements for EV motors, wind turbines, and defense applications, with historic drilling showing high-grade intervals (up to 6.5% TREO over 8m) and a favorable Nd-Pr-to-TREO ratio of 25–40%, rising to 45% in the ST40 zone. The acquisition includes an offtake agreement for up to 60% of future production with Neo Performance Materials, a Western leader in rare earth magnets outside China, ensuring immediate market access and reducing commercialization risk. Combined with Skaergaard's Pd-Pt-Au-Fe-Ti-V-Ga potential, this dual-asset portfolio offers exposure to both traditional precious metals and the fast-growing energy-transition and defense-critical minerals complex, positioning the Company as a rare Western alternative to China-dominated supply chains—a structural advantage that is increasingly valued by policymakers, ESG-focused investors, and strategic industrials seeking supply chain resilience.
Greenland Mines (GRMLW) has established a strategic pathway to unlock multi-metal value at Skaergaard through its partnership with GTK Mintec, which provides an end-to-end platform for metallurgical testing, environmental assessment, and process optimization critical for unlocking the full economic potential of the deposit's complex, fine-grained multi-metal mineralization. This collaboration is not merely additive but transformative, as GTK Mintec's expertise in fine-grained, polymetallic ores—particularly layered mafic intrusions like Skaergaard—enables the Company to design flowsheets that recover not only precious metals (Pd, Pt, Au) but also bulk critical metals (Fe, Ti, V) and specialty elements (Ga, Ge) from both primary ores and tailings streams. The program integrates with ongoing work on ore sorting, pre-concentration, and tailings management, creating a closed-loop system that maximizes resource efficiency and minimizes waste, directly addressing a key unspoken risk in complex deposits: metallurgical recovery uncertainty. By advancing this work in parallel with field campaigns and positioning it as a prerequisite for future development decisions, Greenland Mines is systematically de-risking the project's technical viability far beyond what resource drilling alone can achieve, signaling to investors that the project is advancing toward a bankable feasibility study with credible metallurgical foundations.
The North Atlantic processing strategy—anchored by the non-binding Letter of Intent with an Icelandic industrial site owner—represents a structural, long-term catalyst that could reduce life-of-mine energy costs by over $1 billion while enabling green production of palladium, platinum, gold, and critical metals. This is not a speculative idea but a concrete, phased plan leveraging Iceland's abundant geothermal and hydropower resources to displace diesel-based generation (which currently costs ~$0.20/kWh in remote Arctic operations) with renewable power potentially below $0.03/kWh. The strategy includes pre-processing in Greenland (crushing, ore sorting) to reduce shipment volumes, followed by low-carbon refining in Iceland, creating an integrated value chain that aligns with Western policy goals for secure, transparent, and geopolitically resilient critical mineral supply chains. Management's emphasis on existing brownfield sites in Iceland—offering refurbishable infrastructure, deep-water access, and skilled labor—further reduces capital intensity and timelines, turning a conceptual advantage into an actionable, near-term de-risking lever that enhances both project economics and ESG profile simultaneously, a dual benefit rarely achieved in mining developments.
The concurrent advancement of the Sarfartoq Rare Earths Project—secured via acquisition from Neo Performance Materials—creates a powerful diversification and strategic synergy with Skaergaard, transforming Greenland Mines from a single-project precious metals play into a vertically integrated North Atlantic critical minerals corridor. Sarfartoq provides direct access to Nd-Pr, the two most valuable rare earth elements for EV motors, wind turbines, and defense applications, with historic drilling showing high-grade intervals (up to 6.5% TREO over 8m) and a favorable Nd-Pr-to-TREO ratio of 25–40%, rising to 45% in the ST40 zone. The acquisition includes an offtake agreement for up to 60% of future production with Neo Performance Materials, a Western leader in rare earth magnets outside China, ensuring immediate market access and reducing commercialization risk. Combined with Skaergaard's Pd-Pt-Au-Fe-Ti-V-Ga potential, this dual-asset portfolio offers exposure to both traditional precious metals and the fast-growing energy-transition and defense-critical minerals complex, positioning the Company as a rare Western alternative to China-dominated supply chains—a structural advantage that is increasingly valued by policymakers, ESG-focused investors, and strategic industrials seeking supply chain resilience.
Greenland Mines (GRMLW) remains heavily dependent on the successful completion and positive outcomes of its metallurgical testwork with GTK Mintec, yet the Company provides no concrete timelines, milestones, or success criteria for this program, creating significant opacity around a critical path item. While the framework agreement is framed as a major step forward, the absence of defined deliverables—such as target recovery rates for Pd, Pt, Au, or bulk metals like V and Ti under specific process scenarios—leaves investors unable to assess whether the work will meaningfully de-risk the project or merely generate costly data without actionable outcomes. This is particularly concerning given Skaergaard's known challenges: fine-grained, complex mineralogy that has historically resisted efficient extraction, and the lack of any precedent for commercial-scale processing of this specific ore type. The Company's reliance on GTK Mintec's general reputation in Europe, rather than project-specific pilot results, introduces a material execution risk; if the testwork fails to demonstrate viable flowsheets or reveals unexpectedly high reagent consumption, tailings toxicity, or energy intensity, the entire economic thesis could unravel, especially since no PEA or PFS has been completed to establish baseline expectations.
The North Atlantic processing strategy, while theoretically compelling, hinges on multiple unresolved and high-risk external factors that management does not adequately address, including securing final Icelandic site agreements, obtaining environmental and construction permits in a jurisdiction with strict regulatory oversight, and confirming grid connection feasibility and long-term power purchase agreements for industrial-scale renewable energy. The claim of potential power costs below $0.03/kWh is based on historical industrial user tariffs in Iceland, but these are typically reserved for legacy smelters with long-term contracts—not new greenfield projects—and there is no evidence that Greenland Mines has negotiated or even initiated discussions for such rates. Furthermore, the strategy assumes seamless logistics between East Greenland and Iceland (20–30 hour sailings), yet ignores seasonal ice variability, port infrastructure limitations in remote East Greenland, and the need for specialized ice-class vessels, which could add significant cost and complexity. Without binding off-take agreements for power, firm site commitments, or detailed engineering studies validating the Icelandic hub concept, this remains a high-concept vision vulnerable to delays, cost overruns, or outright failure to materialize, turning a purported $1B+ savings opportunity into a sunk cost burden.
The Sarfartoq acquisition, while strategically appealing, introduces substantial integration and execution risks that are understated in the Company's communications, particularly regarding the uncertainty around the Mineral Resource Estimate and the near-term viability of the project. The historic 2011 PEA is outdated and based on significantly lower rare earth prices; although current Nd-Pr pricing is ~2x those assumptions, the Company has not yet completed an updated resource estimate or PEA, and the 2023 drilling data—while promising—has not been independently validated or incorporated into public disclosures. The reliance on Neo Performance Materials as a 60% offtake partner creates concentration risk: if Neo's own magnet production faces delays, demand shifts, or financial constraints, the offtake commitment may not be honored, leaving Greenland Mines with unsold concentrate and no alternative market access in the near term. Additionally, the project's logistics—while favorable relative to other Greenland rare earth sites—still require substantial capital investment for camp upgrades, drilling, and environmental baseline work, with no clarity on funding sources, and the Company's dual-project focus (Skaergaard and Sarfartoq) risks spreading technical and managerial capacity thin, potentially delaying progress on both fronts amid a challenging financing environment for junior explorers.
Greenland Mines (GRMLW) remains heavily dependent on the successful completion and positive outcomes of its metallurgical testwork with GTK Mintec, yet the Company provides no concrete timelines, milestones, or success criteria for this program, creating significant opacity around a critical path item. While the framework agreement is framed as a major step forward, the absence of defined deliverables—such as target recovery rates for Pd, Pt, Au, or bulk metals like V and Ti under specific process scenarios—leaves investors unable to assess whether the work will meaningfully de-risk the project or merely generate costly data without actionable outcomes. This is particularly concerning given Skaergaard's known challenges: fine-grained, complex mineralogy that has historically resisted efficient extraction, and the lack of any precedent for commercial-scale processing of this specific ore type. The Company's reliance on GTK Mintec's general reputation in Europe, rather than project-specific pilot results, introduces a material execution risk; if the testwork fails to demonstrate viable flowsheets or reveals unexpectedly high reagent consumption, tailings toxicity, or energy intensity, the entire economic thesis could unravel, especially since no PEA or PFS has been completed to establish baseline expectations.
The North Atlantic processing strategy, while theoretically compelling, hinges on multiple unresolved and high-risk external factors that management does not adequately address, including securing final Icelandic site agreements, obtaining environmental and construction permits in a jurisdiction with strict regulatory oversight, and confirming grid connection feasibility and long-term power purchase agreements for industrial-scale renewable energy. The claim of potential power costs below $0.03/kWh is based on historical industrial user tariffs in Iceland, but these are typically reserved for legacy smelters with long-term contracts—not new greenfield projects—and there is no evidence that Greenland Mines has negotiated or even initiated discussions for such rates. Furthermore, the strategy assumes seamless logistics between East Greenland and Iceland (20–30 hour sailings), yet ignores seasonal ice variability, port infrastructure limitations in remote East Greenland, and the need for specialized ice-class vessels, which could add significant cost and complexity. Without binding off-take agreements for power, firm site commitments, or detailed engineering studies validating the Icelandic hub concept, this remains a high-concept vision vulnerable to delays, cost overruns, or outright failure to materialize, turning a purported $1B+ savings opportunity into a sunk cost burden.
The Sarfartoq acquisition, while strategically appealing, introduces substantial integration and execution risks that are understated in the Company's communications, particularly regarding the uncertainty around the Mineral Resource Estimate and the near-term viability of the project. The historic 2011 PEA is outdated and based on significantly lower rare earth prices; although current Nd-Pr pricing is ~2x those assumptions, the Company has not yet completed an updated resource estimate or PEA, and the 2023 drilling data—while promising—has not been independently validated or incorporated into public disclosures. The reliance on Neo Performance Materials as a 60% offtake partner creates concentration risk: if Neo's own magnet production faces delays, demand shifts, or financial constraints, the offtake commitment may not be honored, leaving Greenland Mines with unsold concentrate and no alternative market access in the near term. Additionally, the project's logistics—while favorable relative to other Greenland rare earth sites—still require substantial capital investment for camp upgrades, drilling, and environmental baseline work, with no clarity on funding sources, and the Company's dual-project focus (Skaergaard and Sarfartoq) risks spreading technical and managerial capacity thin, potentially delaying progress on both fronts amid a challenging financing environment for junior explorers.